Trials / Completed
CompletedNCT00893945
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Rockefeller University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study involves cancer research and the purpose is to assess the safety and activity of a type of vaccine as immune therapy for cancer. This vaccine will be made from each participant's own immune cells (called dendritic cells) obtained by blood donation. Dendritic cells (DCs) are immune cells whose role is to identify foreign material in the body (such as bacteria, viruses, or tumor cells). When DCs recognize this material, they use it to activate other cells of the immune system to mount an attack against that foreign material. In the Laboratory of Molecular Neuro-Oncology, each participant's DCs will be loaded with samples of their own tumor cells that were obtained at surgical resection. These tumor cells are killed in the laboratory using a special protocol, and then "fed" to the DCs. The DCs "eat" this material, and these "fed" DCs make up the vaccine.
Detailed description
If you are eligible, and you decide to join this research study, you will get two to three shots of the experimental vaccine, each three weeks apart. You will then have a follow up period where we will monitor you and your medical records for any affects of the experimental treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DC/AAT | Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens. |
| DRUG | DC/AAT-Flu | Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT |
| DRUG | DC/KLH | Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2009-05-06
- Last updated
- 2014-12-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00893945. Inclusion in this directory is not an endorsement.